SILO PHARMA INC (SILO) Fundamental Analysis & Valuation

NASDAQ:SILO • US82711P2011

Current stock price

0.455 USD
+0.01 (+2.92%)
At close:
0.4557 USD
+0 (+0.15%)
After Hours:

This SILO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SILO Profitability Analysis

1.1 Basic Checks

  • In the past year SILO has reported negative net income.
  • In the past year SILO has reported a negative cash flow from operations.
  • In the past 5 years SILO reported 4 times negative net income.
  • SILO had a negative operating cash flow in each of the past 5 years.
SILO Yearly Net Income VS EBIT VS OCF VS FCFSILO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M

1.2 Ratios

  • SILO has a Return On Assets (-55.59%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -67.05%, SILO perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
Industry RankSector Rank
ROA -55.59%
ROE -67.05%
ROIC N/A
ROA(3y)-54.21%
ROA(5y)-34.48%
ROE(3y)-71.41%
ROE(5y)-44.89%
ROIC(3y)N/A
ROIC(5y)N/A
SILO Yearly ROA, ROE, ROICSILO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

  • SILO has a Gross Margin of 38.61%. This is in the better half of the industry: SILO outperforms 72.62% of its industry peers.
  • SILO's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SILO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.22%
GM growth 5YN/A
SILO Yearly Profit, Operating, Gross MarginsSILO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SILO Health Analysis

2.1 Basic Checks

  • SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SILO has more shares outstanding
  • SILO has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SILO Yearly Shares OutstandingSILO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
SILO Yearly Total Debt VS Total AssetsSILO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -1.48, we must say that SILO is in the distress zone and has some risk of bankruptcy.
  • SILO has a Altman-Z score (-1.48) which is in line with its industry peers.
  • There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.48
ROIC/WACCN/A
WACC9.51%
SILO Yearly LT Debt VS Equity VS FCFSILO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 11.36 indicates that SILO has no problem at all paying its short term obligations.
  • The Current ratio of SILO (11.36) is better than 82.91% of its industry peers.
  • A Quick Ratio of 11.36 indicates that SILO has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 11.36, SILO belongs to the best of the industry, outperforming 83.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.36
Quick Ratio 11.36
SILO Yearly Current Assets VS Current LiabilitesSILO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SILO Growth Analysis

3.1 Past

  • SILO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.85%, which is quite impressive.
  • The Revenue has decreased by 0.00% in the past year.
  • The Revenue has been growing slightly by 0.99% on average over the past years.
EPS 1Y (TTM)48.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.9%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.90% on average over the next years. This is a very strong growth
  • SILO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 374.06% yearly.
EPS Next Y-2.86%
EPS Next 2Y-26.49%
EPS Next 3Y-20.01%
EPS Next 5Y30.9%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y374.06%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SILO Yearly Revenue VS EstimatesSILO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
SILO Yearly EPS VS EstimatesSILO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. SILO Valuation Analysis

4.1 Price/Earnings Ratio

  • SILO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILO Price Earnings VS Forward Price EarningsSILO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILO Per share dataSILO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as SILO's earnings are expected to decrease with -20.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.49%
EPS Next 3Y-20.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SILO Dividend Analysis

5.1 Amount

  • No dividends for SILO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SILO Fundamentals: All Metrics, Ratios and Statistics

SILO PHARMA INC

NASDAQ:SILO (5/1/2026, 8:00:02 PM)

After market: 0.4557 +0 (+0.15%)

0.455

+0.01 (+2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-27
Earnings (Next)05-07
Inst Owners8.57%
Inst Owner Change0.01%
Ins Owners1.57%
Ins Owner Change8.56%
Market Cap6.45M
Revenue(TTM)72.00K
Net Income(TTM)-4.23M
Analysts82.86
Price TargetN/A
Short Float %3.26%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 89.55
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.01
BVpS0.44
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -55.59%
ROE -67.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.61%
FCFM N/A
ROA(3y)-54.21%
ROA(5y)-34.48%
ROE(3y)-71.41%
ROE(5y)-44.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.22%
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5042.98%
Cap/Sales 798.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.36
Quick Ratio 11.36
Altman-Z -1.48
F-Score3
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.9%
EPS Next Y-2.86%
EPS Next 2Y-26.49%
EPS Next 3Y-20.01%
EPS Next 5Y30.9%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y374.06%
EBIT growth 1Y9.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.58%
OCF growth 3YN/A
OCF growth 5YN/A

SILO PHARMA INC / SILO Fundamental Analysis FAQ

What is the fundamental rating for SILO stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILO.


What is the valuation status of SILO PHARMA INC (SILO) stock?

ChartMill assigns a valuation rating of 0 / 10 to SILO PHARMA INC (SILO). This can be considered as Overvalued.


What is the profitability of SILO stock?

SILO PHARMA INC (SILO) has a profitability rating of 1 / 10.


What is the financial health of SILO PHARMA INC (SILO) stock?

The financial health rating of SILO PHARMA INC (SILO) is 7 / 10.